PsiOxus commences MT-102 Phase II study for treatment of cancer- and age-related wasting
March 04, 2017
"Cachexia is a powerful risk factor for increased morbidity and mortality, so breaking this progressive cycle of weight loss, weakness and fatigue is critical for improving the outcome of many serious diseases, such as cancer," said PsiOxus CEO Dr. John Beadle. "MT-102 is unique in that it reduces muscle breakdown (catabolism) as well as increasing muscle build-up (anabolism). This clinical trial aims to demonstrate this Anabolic Catabolic Transforming activity in the context of late stage cancer patients. We are excited to enter this next phase in clinical development, and look forward to moving MT-102 one step closer to treating these serious diseases."
Cachexia is a direct cause of as much as 40 percent of all cancer patient mortalities. Cachexia causes an anabolic and catabolic imbalance resulting in cell death and tissue wasting. Most research activity to date has focused on pro-anabolic treatment. PsiOxus has chosen to focus its approach on anti-catabolic approaches. MT-102 has both anti-catabolic and pro-anabolic activity referred to as an Anabolic Catabolic Transforming Agent (ACTA) and operates on both of the fundamental mechanisms using a single agent.
Source: PsiOxus Therapeutics, Ltd.